Interferon beta-1a in relapsing-remitting multiple sclerosis.
The accumulated results from multiple trials have unequivocally demonstrated beneficial effects of interferon beta-1a on disease activity in relapsing-remitting multiple sclerosis, both for clinical and magnetic resonance endpoints. New data suggest that low doses administered once weekly are relatively ineffective and that higher, more frequent doses are required for optimal benefit.